Autoimmune disease is a broad class of disorders in which the immune system attacks the body’s own tissues and organs, and its clinical use here is centered on disease prognosis and therapeutic response prediction. Non-coding RNAs are highlighted as prognostic biomarkers in non coding rnas, suggesting a biomarker-driven approach to stratifying patients and anticipating outcomes. The field is also expanding into cell therapy, with car nk cell therapy being discussed as a treatment modality for autoimmune disease. Another emerging therapeutic angle is ERAP1, which is described as a target in this disease category, linking autoimmune pathology to inhibitor optimization efforts. Overall, the literature points to a shift from descriptive immunology toward precision medicine, combining biomarker assessment with targeted and cellular therapies.
Prognosis and biomarker prediction
- Non-coding RNAs were reviewed as prognostic biomarkers for autoimmune disease, emphasizing their potential for disease prognosis and therapeutic response prediction. (PMID:41654009)
- The review frames autoimmune disease as a setting where biomarker-based risk stratification may improve clinical decision-making. (PMID:41654009)
Cell therapy
- car nk cell therapy is reported to be expanding into autoimmune disease, indicating growing interest in engineered innate immune cell approaches beyond oncology. (PMID:42003566)
- A 2026 Immunology and Cell Biology paper on CAR-NK cell-based therapies highlights translational and regulatory breakthroughs relevant to autoimmune indications. (PMID:42003566)
Targeted therapy
- ERAP1 is described as an emerging target in autoimmune disease, linking antigen-processing biology to therapeutic development. (PMID:41973545)
- A 2026 Journal of Medicinal Chemistry study on automated molecular design in BRADSHAW focused on optimizing ERAP1 inhibitors, supporting target-directed drug discovery for this disease area. (PMID:41973545)